Surgical resection for Bismuth type IV perihilar cholangiocarcinoma
Executive Summary
Traditionally, Bismuth type IV perihilar cholangiocarcinoma has been categorized as an unresectable disease by major staging systems and clinical guidelines. However, a retrospective analysis of 332 patients at Nagoya University (2006–2015) demonstrates that a resection-based strategy is technically feasible and provides a significant survival advantage. Of the 332 patients, 65.1% (216) underwent resection, achieving a five-year survival rate of 32.8%, compared to a mere 1.5% for those with unresected tumors. While the procedures are technically demanding—characterized by high morbidity (41.7% Clavien–Dindo grade III or more)—they can be performed with low 90-day mortality (1.9%). Key factors for success include specialized preoperative biliary drainage, portal vein embolization, and aggressive vascular resection.
Overview of Bismuth Type IV Classification
The Bismuth system classifies perihilar cholangiocarcinoma based on the extent of intrahepatic biliary invasion. Type IV tumors are characterized by bilateral involvement of the second-order intrahepatic bile ducts.
Traditional Consensus: Major staging classifications (Blumgart’s system, UICC system) and the American Hepato-Pancreato-Biliary Association (AHPBA) guidelines have historically designated type IV tumors as unresectable.
The Shift in Paradigm: Improvements in surgical techniques and perioperative management have led some surgeons to challenge this designation. The current study suggests the traditional "unresectable" label may no longer be valid for all patients.
Study Methodology and Patient Characteristics
The study reviewed medical records of consecutive patients treated between 2006 and 2015.
Cohort Size: 332 patients with Bismuth type IV tumours (49.8% of all perihilar cholangiocarcinoma cases treated during the interval).
Patient Demographics: 195 men and 137 women; median age of 67.
Initial Resectability: 266 patients were considered potentially resectable at referral. Ultimately, 216 patients underwent resection.
Reasons for Unresectability (n=116):
Distant metastatic disease (16.0%)
Locally advanced disease (11.1%)
Poor functional liver reserve (5.1%)
Poor general condition (2.7%)
Surgical Strategy and Technical Demands
Resection for type IV tumors typically involves complex, extended hepatectomies. Unlike the classical preference for right-sided hepatectomy in perihilar cases, this study found a left-sided predominance in type IV tumors.
Surgical Procedures
Key Operative Data
Duration: Median of 607 minutes (range: 356–1045 min).
Blood Loss: Median of 1357 ml (range: 209–10,349 ml).
Vascular Resection: Involved the portal vein alone (56 patients), hepatic artery alone (18), or both (57).
Preoperative Management and Biliary Drainage
Optimal management of the biliary tree and future liver remnant (FLR) is critical for reducing postoperative liver failure.
Biliary Drainage:
Endoscopic Nasobiliary Drainage (ENBD): Preferred over Endoscopic Biliary Stenting (EBS). EBS was associated with a higher incidence of post-drainage ascending cholangitis (32% vs. 23.1% for ENBD).
Percutaneous Transhepatic Biliary Drainage (PTBD): Identified as an independent negative prognostic factor for survival, likely due to PTBD-associated seeding metastasis.
Portal Vein Embolization (PVE): Performed in 159 patients to increase the FLR. The percentage of FLR increased from a median of 34.1% to 43.5% post-embolization.
Liver Function Assessment: Indocyanine green clearance rate was used to assess the FLR, with a surgical cut-off value of 0.05.
Clinical and Pathological Outcomes
The study highlights that while the surgery is aggressive, the oncological outcomes justify the risk in selected patients.
R Status: R0 resection (negative margins) was achieved in 156 patients (72.2%). Ductal involvement with carcinoma in situ was considered negative (R0).
Morbidity: 90 patients (41.7%) experienced complications of Clavien–Dindo grade III or more. Liver failure (31.0%) and bile leakage (26.4%) were the most common.
Mortality: The 90-day mortality rate was 1.9% (4 deaths), demonstrating that high-volume centers can manage these complex cases safely.
Survival Rates:
Resected: 32.8% at 5 years (Median Survival Time [MST]: 34.9 months).
Unresected: 1.5% at 5 years (MST: 11.2 months).
pN0 M0 subgroup: 53.0% survival at 5 years.
Prognostic Factors for Survival
Multivariable Cox proportional hazards modeling identified several independent negative predictors for long-term survival:
PTBD: Increased risk of seeding metastasis.
Homologous Blood Transfusion: Had a negative impact on survival.
Nodal Status (pN1): Significantly worse survival than pN0.
Distant Metastasis (pM1): Though pM1 survival (MST 18.8 months) was still better than the unresected group (MST 11.2 months).
Comparative Context: Resection vs. Transplantation
The study provides a critical comparison between the Nagoya resection-based strategy and the Mayo Clinic liver transplantation protocol.
Eligibility: At least two-thirds of the resected patients in this study would not have met the strict criteria for liver transplantation (e.g., tumor size <3 cm and pN0 disease).
Outcomes: The 5-year survival rate of 53% for pN0 M0 patients after resection is comparable to results reported for de novo cholangiocarcinoma treated with liver transplantation.
Conclusion on Staging: The study suggests that AJCC T4 tumors (type IV) are not inherently unresectable and that surgery should be considered oncologically rational.
Final Conclusion
While Bismuth type IV perihilar cholangiocarcinoma is technically demanding and carries a high risk of complications, a resection-based strategy offers a significant survival benefit over non-surgical management. Success is predicated on meticulous preoperative biliary drainage (preferring ENBD), portal vein embolization, and the ability to perform complex trisectionectomies with vascular reconstruction. The traditional classification of type IV tumors as "unresectable" is increasingly challenged by these clinical results.
